Specify a stock or a cryptocurrency in the search bar to get a summary
Connect Biopharma Holdings Ltd
CNTBConnect Biopharma Holdings Limited, a clinical-stage biopharmaceutical company, focuses on developing therapies to treat T cell-driven inflammatory diseases. The company is building a pipeline of small molecules and antibodies using functional T cell assays to screen and discover potent product candidates against validated immune targets. Its lead product candidate is CBP-201, an antibody to target interleukin-4 receptor alpha in development for the treatment of atopic dermatitis (AD) and asthma. The company's product candidates also comprise CBP-307, a modulator of S1P1 T cell receptor and is in development for the treatment of ulcerative colitis; and CBP-174, a peripherally acting antagonist of histamine receptor 3 in development for the treatment of pruritus associated with skin inflammation. Connect Biopharma Holdings Limited was founded in 2012 and is headquartered in San Diego, California. Address: East R&D Building, Taicang, China, 215400
Analytics
WallStreet Target Price
7.05 USDP/E ratio
–Dividend Yield
–Current Year
Last Year
Current Quarter
Last Quarter
Current Year
Last Year
Current Quarter
Last Quarter
Key Figures CNTB
Dividend Analytics CNTB
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History CNTB
Stock Valuation CNTB
Financials CNTB
Results | 2019 | Dynamics |